Therapeutics News and Research

RSS

ACGT awards $500,000 to advance immunotherapy approach for treating solid tumors

A scientific team led by Brian Brown, PhD, Professor of Genetics and Genomic Sciences and Associate Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai (New York, New York), has been awarded $500,000 from Alliance for Cancer Gene Therapy to advance a promising immunotherapy approach to fight lung cancer and other solid tumor cancers.

1 Mar 2021

COVID-19 CG tracks local SARS-CoV-2 mutations by geographical location

Genomic surveillance of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has varied across countries. England's increased coronavirus sequencing helped it uncover the B.1.1.7 variant last fall. In contrast, countries such as the United States have reported little sequencing data.

28 Feb 2021

Bacteria use slimy strategy to defeat antibiotics that fight cystic fibrosis

University of Montana researchers and their partners have discovered a slimy strategy used by bacteria to defeat antibiotics and other drugs used to combat infections afflicting people with cystic fibrosis. The research was published Feb. 23 in the journal Cell Reports.

27 Feb 2021

Critical Path Institute and global partners establish Ataxia Consortium

Critical Path Institute (C-Path) today announced the launch of the Critical Path to Therapeutics for the Ataxias (CPTA) Consortium, a public-private partnership focused on optimizing clinical trials for inherited ataxias.

27 Feb 2021

Inhalable nanobody shows potent anti-SARS-CoV-2 activity in vivo

Researchers have developed a stable and ultrapotent homotrimeric Pittsburgh inhalable Nanobody 21 (PiN-21) against SARS-CoV-2 infection in Syrian hamsters. They demonstrated the high therapeutic efficacy of this homotrimeric Nb, leveraging both intranasal and aerosol delivery.

26 Feb 2021

Nanobowls show potential for diagnostics and treatment of Alzheimer's

Scientists are still a long way from being able to treat Alzheimer's Disease, in part because the protein aggregates that can become brain plaques, a hallmark of the disease, are hard to study.

26 Feb 2021

Study shows why SARS-CoV-2 is more infectious than SARS-CoV-1

Coronavirus outbreaks have occurred periodically, but none have been as devastating as the COVID-19 pandemic.

26 Feb 2021

Researchers identify a new mechanism underlying atherosclerosis

Glycomics researchers at the University of Alberta and CHU Sainte-Justine have reported a discovery that could lead to new treatments for cardiovascular disease.

25 Feb 2021

FDA approval provides targeted treatment option for patients with rare DMD mutation

Today, the U.S. Food and Drug Administration granted approval for Amondys 45 (casimersen) injection for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping (Exons are pieces of DNA that provide information for making proteins in a person's genome).

25 Feb 2021

Canadian pilot study uses gene therapy to successfully treat patients with Fabry disease

Results of a world-first Canadian pilot study on patients treated with gene therapy for Fabry disease show that the treatment is working and safe.

25 Feb 2021

Research shows effective strategy to target the SARS-CoV-2 spike protein

The virus that causes COVID-19 belongs to the family of coronaviruses, "corona" referring to the spikes on the viral surface. These spikes are not static - to infect cells, they change shapes.

25 Feb 2021

'Miracle poison' can target a variety of different proteins

Researchers prove they can engineer proteins called proteases to find new targets with high selectivity, a critical advance toward potential new treatments for everything from neuro-regeneration to cytokine storm.

25 Feb 2021

Corticosteroid receptor inhibitor shows anti-SARS-CoV-2 activity in vivo

A team of researchers examined PT150, which is an allosteric modulator of androgen and glucocorticoid receptors, to assess whether it had any antiviral activity or immunomodulatory activity to decrease the hyperinflammatory response of SARS-CoV-2 infection.

24 Feb 2021

New glioma-targeted nano-therapeutic offers a potential treatment for glioblastomas

With a survival rate of only five years, the most common and aggressive form of primary brain tumor, glioblastoma multiforme, is notoriously hard to treat using current regimens that rely on surgery, radiation, chemotherapy, and their combinations.

24 Feb 2021

Study: Abundance of iron can drive cancer cell death in neuroblastoma

Neuroblastoma is a cancer that develops in nerve tissue, most commonly in the glands around the kidneys. The gene MYCN is overexpressed in 20-25% of neuroblastoma, and MYCN-amplified neuroblastoma contributes to a considerable percentage of pediatric cancer-related deaths.

24 Feb 2021

Two potent SARS-CoV-2 neutralizing antibodies effective against B.1.351 and B.1.1.7 variants

By analyzing the cryoEM structures of antibodies against the SARS-CoV-2 virus, researchers report that the neutralizing capabilities of two antibodies are not affected by new strains as these antibodies target regions of the virus away from the ACE2 binding regions.

23 Feb 2021

After billions of dollars and dozens of wartime declarations, why are vaccines still in short supply?

The U.S. government has invested billions of dollars in manufacturing, used a wartime act dozens of times to boost supplies and yet there's still not enough covid vaccine on the way to meet demand — or even the government's own goals for national immunization.

23 Feb 2021